SAA2 and amyloidosis: ➢ SAA is significantly elevated during FMF attacks and remains increased between attacks➢ SAA is higher among asymptomatic heterozygous carriers of MEFV mutations compared to HC, potentially leading to development of amyloidosis (phenotype II)➢ SAA level monitoring should be used for assessment of and reinforcing patients compliance for therapy